Cambridge-based Hemab Therapeutics is getting ready to test Wall Street's mood. The biotech has filed paperwork to go public, pitching an offering that would raise about $212 million. The company is marketing roughly 11.8 million shares at an indicated price range of $16 to $18 per share, a setup that would value Hemab at roughly $706 million at the top end. Hemab develops subcutaneous therapies for rare bleeding disorders and says the cash will fuel clinical work on its lead candidates.
Terms of the offering and who's backing it
According to Bloomberg, the filing lists the Novo Nordisk Foundation among Hemab's biggest investors and shows the company marketing 11.8 million shares at $16 to $18 apiece. Bloomberg also notes that the top of that range would put Hemab's market value at about $705.7 million based on the outstanding shares in the prospectus.
Where the money would go
In its SEC prospectus, Hemab says it intends to use the net proceeds, together with existing cash, to fund clinical development of sutacimig for Glanzmann thrombasthenia and Factor VII deficiency and to advance HMB-002 for Von Willebrand Disease, as well as additional discovery and general corporate purposes. The prospectus shows Hemab had $185.5 million in cash, cash equivalents and marketable securities as of Dec. 31, 2025 and reported a net loss of $63.9 million for 2025.
Pipeline and clinical status
Hemab's lead program, sutacimig (HMB-001), is described as a bispecific antibody in early clinical development, with a Phase 1/2 study for Glanzmann thrombasthenia, Phase 2 activity in Factor VII deficiency and a planned Phase 3, while HMB-002 is in Phase 1/2 for Von Willebrand Disease, as outlined by market summaries. TradingView also notes regulatory designations tied to sutacimig and licensing arrangements for key IP.
How this fits into Boston's biotech scene
Hemab's filing lands amid a renewed push of life-science companies toward public markets this spring, joining other entrants from the Boston/Cambridge cluster. BioCentury flagged Hemab alongside peers, and our earlier Hoodline coverage of Seaport put the local IPO momentum in context for Boston readers.
Deal mechanics and who's running the books
Market summaries show the syndicate includes Goldman Sachs & Co. LLC, Jefferies and Evercore ISI as bookrunners, with Wedbush PacGrow listed as lead manager, and that Hemab has applied to list on the Nasdaq Global Select Market under the proposed symbol "COAG." TradingView summarizes those details from the registration statement.
What to watch next
Investors should track the eventual price set by the underwriters and early demand. The company's prospectus warns the anticipated net proceeds will not be sufficient to fund product candidates through regulatory approval and that additional capital will likely be required. For local readers, the debut will also be a measure of whether Boston-area rare-disease plays can regain traction in the public markets.
